Dr. Lloyd Damon is a board-certified medical oncologist based in San Francisco, California. He graduated from the University of Michigan Medical School and later did his residency in internal medicine at the UCSF. Dr. Damon has been practicing oncology for about 20 years and is currently associated with the UCSF Medical Center. He has also contributed to three research publications.
University of Michigan
American Board of Internal Medicine - Oncology
Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic S...
Mannis, G. N.,Martin, T. G.,Damon, L. E.,Andreadis, C.,Olin, R. L.,Kong, K. A.,Faham, M.,Hwang, J.,Ai, W. Z.,Gaensler, K. M.,Sayre, P. H.,Wolf, J. L.,Logan, A. C.; Biol. Blood Marrow Transplant.. 2016 Feb 24.See more >>
Long-Term Outcomes of Patients with Intermediate-Risk Acute Myeloid Leukemia Treated with Autologous Hematopoietic Cell Transplant in First Complete Remission.
Mannis, G. N.,Martin, T. G.,Damon, L. E.,Logan, A. C.,Olin, R. L.,Flanders, M. D.,Ai, W. Z.,Gaensler, K. M.,Kaplan, L. D.,Sayre, P. H.,Smith, C. C.,Wolf, J. L.,Andread...; Leuk. Lymphoma. 2015 Oct 23.See more >>
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, doubl...
Ravandi, F.,Ritchie, E. K.,Sayar, H.,Lancet, J. E.,Craig, M. D.,Vey, N.,Strickland, S. A.,Schiller, G. J.,Jabbour, E.,Erba, H. P.,Pigneux, A.,Horst, H. A.,Recher, C.,K...; Lancet Oncol.. 2015 Aug 04.See more >>